Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery

Mizuho Asada | Masashi Nagata | Tomohiro Mizuno | Tokuiro Uchida | Naoki Kurashima | Hiromitsu Takahashi | Koshi Makita | Hirokuni Arai

Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery

Mizuho Asada

Masashi Nagata

Tomohiro Mizuno

Tokuiro Uchida

Naoki Kurashima

Hiromitsu Takahashi

Koshi Makita

Hirokuni Arai

Hirotoshi Echizen

Masato Yasuhara

Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

Department of Pharmacokinetics and Pharmacodynamics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

Department of Cardiovascular Surgery, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

Department of Anesthesiology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

Medical Engineering Center, Medical Hospital of Tokyo Medical and Dental University (TMDU), Tokyo, Japan

Department of Pharmacotherapy, Meiji Pharmaceutical University, Tokyo, Japan

Correspondence
Masashi Nagata, Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, Japan.
Email: mna-mpha@tmd.ac.jp

Funding information
JSPS KAKENHI, Grant/Award Number: JP17H00452

Abstract
The aim of the study was to evaluate the disposition of plasma unbound cefazolin in patients undergoing cardiothoracic surgery with cardiopulmonary bypass (CPB). Adult patients undergoing cardiothoracic surgery with CPB were enrolled in the study. Cefazolin sodium was given intravenously before skin incision (1 g) and at the beginning of CPB (2 g). Thereafter, an additional dose (1 g) was given every 4 hours. Seven to ten blood samples were collected before and during surgery. Plasma total and unbound (ultrafiltrated) cefazolin concentrations were analyzed using an HPLC-UV method. Plasma protein binding was analyzed with the Langmuir model. Twenty-seven patients (aged 70 ± 12 years, body weight 62 ± 12 kg, mean ± SD) with GFR > 30 mL min⁻¹ completed the study. There was a significant (P < 0.001) increase in median plasma unbound fraction of cefazolin from 21% before skin incision to 45% during CPB (P < 0.001), which was accompanied by a significant (P < 0.001) reduction in median plasma albumin concentration from 36 to 27 g L⁻¹. Plasma concentrations of unbound cefazolin exceeded the assumed target thresholds of 2 μg mL⁻¹ in all samples and of 8 μg mL⁻¹ in all but one of 199 samples. The increased plasma unbound fraction of cefazolin would be attributable to dilutional reduction of serum albumin at the beginning of CPB and to saturable plasma protein binding of cefazolin. These data reveal CPB may alter the plasma protein binding and possibly distribution of cefazolin. Further studies are warranted to reappraise the protocol of antimicrobial prophylaxis with cefazolin in patients undergoing surgery with CPB.

KEYWORDS
cardiopulmonary bypass, cefazolin, plasma protein binding, surgical site infection, unbound fraction

Abbreviations:
CPB, cardiopulmonary bypass; GFR, glomerular filtration rate; HPLC, high performance liquid chromatography; ISF, interstitial fluid; MSSA, methicillin-sensitive Staphylococcus aureus.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2018 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
INTRODUCTION

Surgical site infection (SSI) is one of the major postoperative complications and is associated with increased morbidity and mortality.\(^1\)\(^2\) Particularly, SSIs (such as mediastinitis) that develop in patients undergoing cardiothoracic surgery are associated with a high mortality. Previous meta-analyses revealed that antimicrobial prophylaxis used in cardiothoracic surgery is associated with better surgical outcomes.\(^3\)\(^4\) While cardiothoracic surgery is often performed with cardiopulmonary bypass (CPB), there is a paucity of knowledge about changes that may occur in the pharmacokinetics of drugs during CPB. As a result, consensus has not been attained about the choice and dosing protocols of antibiotics for these patients.\(^5\) The guidelines of the American Society of Health-System Pharmacists recommend that traditional antimicrobial prophylaxis protocols for general surgery should not be changed for patients undergoing cardiothoracic surgery with CPB, unless further clinical outcome data obtained from well-designed studies are available.\(^5\) Nevertheless, recent studies argued that conventional regimens of cefazolin prophylaxis for these patients may not be reliable in maintaining a target plasma threshold (for example, total drug concentration of 40 mg/L\(^1\)) occurs, and it may increase the volume of distribution and alter plasma protein binding of drugs that have a small volume of distribution and extensive plasma protein binding. In addition, heparin is routinely administered intravenously at 300 to 400 U kg\(^-1\) per hour during CPB, in order to achieve an adequate degree of anticoagulation. A heparin-induced increase in plasma free fatty acids may competitively displace drugs from their albumin-binding sites.\(^9\) Furthermore, CPB may affect systemic elimination of drugs by altering hepatic and/or renal blood flow.\(^9\)\(^10\)

Current guidelines recommend intravenous cefazolin sodium as the drug of choice for antimicrobial prophylaxis in patients undergoing surgery, due to its excellent activity against common pathogens causing SSI.\(^11\) Since cefazolin binds extensively to albumin (80%-86%)\(^6\)\(^7\) and has a small volume of distribution (10 L per body),\(^6\) its disposition may be particularly susceptible to CPB-induced physiological changes. Indeed, previous studies reported a 28%-50% decrease in plasma total cefazolin concentration during CPB.\(^12\)\(^13\) Collectively, there is a paucity of knowledge about the impact of CPB on the disposition of cefazolin. Here, we report the disposition of total and unbound cefazolin throughout cardiothoracic surgery performed with CPB, with reference to the target plasma unbound drug concentration.

MATERIALS AND METHODS

2.1 Patients and CPB procedures

Adult patients who underwent cardiothoracic surgery with CPB at the Medical Hospital, Tokyo Medical and Dental University between May 2015 and July 2017 were enrolled in the study. The protocol of the present study was approved by the Ethics Committee of the Faculty of Medicine, Medical Research Tokyo Medical and Dental University, Tokyo, Japan before the study was begun (authorization number: M2000-1895). Prior to participation in the study, each patient provided written informed consent. Exclusion criteria were a history of hypersensitivity to cephalosporins or penicillins, comorbidities of severe renal dysfunction (estimated glomerular filtration rate (GFR) < 30 ml/min\(^-1\)) and chronic liver diseases, active infection at the time of surgery, and antimicrobial treatment during one week prior to operation. GFR was estimated (eGFR) according to the equation established for Japanese:\(^14\)

\[
eGFR = 194 \times \frac{\text{[serum creatinine]\(^{-1.094}\)}}{\text{[age]\(^{-0.287}\)} \times \text{body surface area}\(\frac{1}{1.73}\)}\text{(ml min}\(^{-1}\text{)}\text{) for men}
\]

\[
eGFR = 194 \times \frac{\text{[serum creatinine]\(^{-1.094}\)}}{\text{[age]\(^{-0.287}\)} \times \text{body surface area}\(\frac{1}{1.73}\)} \times 0.793\text{(ml min}\(^{-1}\text{)}\text{) for women}
\]

CPB was performed using the Advanced Perfusion System 1 (Terumo, Tokyo, Japan). The CPB circuit was primed with 1100-1950 ml of fluid containing 2 ml kg\(^{-1}\) mannitol, 500 ml of hydroxyethyl starch products, and approximately 500 ml of lactated Ringer solution. During CPB, the Hepcon Hemostasis Management System (HMS) Plus System (Medtronic International Ltd., Hong Kong) was used for automatic titration of heparin doses. CPB was conducted at a flow rate of 2.4 x body surface area L m\(^{-2}\) min\(^{-1}\).

2.2 Antimicrobial prophylaxis

Cefazolin sodium for injection (Nichiko, Toyama, Japan) at a dose of 1 g was infused intravenously over 30 minutes. The infusion was started approximately 60 minutes before skin incision. Thereafter, additional dose was administered every 4 hours. In addition, 2 g of cefazolin was added to the priming solution of the CPB circuit. (Figure 1).

2.3 Blood Samplings

Blood samples were collected before the preoperative dose was given and 30 minutes after the completion of infusion. Blood samples were also taken immediately before and 30 minutes after the start and the end of CPB, and at wound closure. When an additional dose of cefazolin was needed for lengthy operation with CPB, blood samples were also obtained immediately before and 30 minutes after completion of the infusion of the supplemental
A dose of cefazolin was administered before the initiation of CPB. If the course of surgery was complicated before CPB initiation, the second arrowheads (▼) represent blood samplings. The horizontal box represents the duration of CPB. The times of skin incision and wound closure are indicated by up arrows (↑). In a patient whose course of surgery was complicated before CPB initiation, the second dose of cefazolin was administered before the initiation of CPB.

Dose. During CPB, blood samples (2.5 mL) for plasma cefazolin and albumin assays were withdrawn by anesthesiologists from an arterial catheter placed in the radial artery before and after CPB, and by medical engineers from the pump circuit. Blood samples were collected into serum separating tubes in which tetrahydrolipstatin (2.5 mg) had been added to a final concentration of 1 mg L⁻¹. Tetrahydrolipstatin was added to blood samples to prevent in vitro lipolysis of triglyceride by heparin after sample collection. Strictly speaking, serum was separated from blood samples taken before and during surgery until CPB was commenced, but plasma was separated from those taken during CPB and thereafter when patients' blood was anticoagulated by heparin in vivo. For avoiding unnecessary complexity, we describe blood samples obtained by centrifugation of tubes as plasma hereafter. This is because our major interests were to study the disposition of cefazolin during and after CPB. Blood samples were centrifuged at 3000 g for 10 minutes, and the separated plasma samples were kept in ice water bath until protein binding study. Plasma albumin concentrations were determined by the bromocresol green method using the A/G B-test kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan) according to the manufacturer's instructions.

2.4 | Plasma cefazolin analysis

Total and unbound cefazolin concentrations in plasma were analyzed using a high performance liquid chromatography (HPLC) with UV detection method according to that reported by Nygard G. et al. with minor modifications. Briefly, for assay of total cefazolin, 100 μL of plasma and 200 μL of an internal standard solution containing cephalin at 20 μg mL⁻¹ in acetonitrile were mixed vigorously for 10 seconds, and then the mixture was centrifuged at 1700g for 5 minutes. Sixty microliters of the supernatant was mixed well with 340 μL of a 0.01 mol L⁻¹ NaH₂PO₄ solution, and 50 μL of the mixture was injected into the HPLC column. The HPLC system employed in the present study consisted of a solvent delivery pump (Prominence LC-20AD, Shimadzu Co., Kyoto, Japan), a TSKgel ODS-80TM column (5 μm, 4.6 mm i.d. × 150 mm; TOSOH, Japan) maintained at 40°C in a column oven (CTO-20AC, Shimadzu), and an ultraviolet detector (SPD-M20A, Shimadzu) set at 254 nm. The mobile phase consisted of a mixture of 0.01 mol L⁻¹ NaH₂PO₄ and acetonitrile (88:12, in volume percent), and was used at a flow rate of 1.0 mL min⁻¹. For assay of unbound cefazolin, plasma samples were ultrafiltered with a Nanosep ultrafiltration device equipped with 10 K molecular weight cut-off membrane (Pall Corporation, Port Washington, NY, USA). We performed plasma protein binding study within 12 hours after sampling. Plasma samples kept in ice water bath were warmed up at 37°C in a temperature-controlled water bath for 10 minutes, and then were subject to ultrafiltration. Ultrafiltration was performed by centrifugation at 1000g for 20 minutes at room temperature. Fifty microliters of the ultrafiltrate and 50 μL of the internal standard solution containing cephapirin of 20 μg mL⁻¹ in acetonitrile were mixed vigorously for 10 seconds, and then centrifuged at 1700g for 5 minutes. Sixty microliters of the supernatant was mixed well with 340 μL of a 0.01 mol L⁻¹ NaH₂PO₄ solution, and 50 μL of the mixture was injected into the HPLC column. We found no significant absorption of cefazolin to ultrafiltration filters or device. The lower limit of detection with a signal to noise ratio of 3 or greater was 0.1 μg mL⁻¹. Intra- and interday coefficients of variation of cefazolin assay were less than 5.8% and 6.5%, respectively.

2.5 | Target plasma cefazolin concentrations

We set plasma unbound cefazolin concentrations of 2 and 8 μg mL⁻¹ as the target thresholds for antimicrobial prophylaxis against SSI. These values are consistent with the breakpoints of Clinical and Laboratory Standard Institute (CLSI) for methicillin-resistant Staphylococcus aureus and susceptible Gram-negative pathogens (e.g. Enterobacteriaceae). Eight μg mL⁻¹ of plasma unbound cefazolin concentration was used in a recent study as a target threshold level in patients undergoing cardiac surgery with CPB. Seven

2.6 | Comparisons between measured plasma unbound cefazolin concentrations and those estimated using the Langmuir model

Decroix et al. revealed that cefazolin is bound exclusively to albumin and that binding is saturable. Using the Langmuir model (see below), they found that cefazolin has an affinity constant (Kᵣ) of 16 600 ± 1600 mol L⁻¹ and one saturable binding site (n = 0.73 ± 0.02). The Langmuir model is formulated as follows:
\[
\frac{C_b}{C_{prot}} = \frac{n \cdot K_a \cdot C_u}{1 + K_a \cdot C_u} \quad (1)
\]

where \(C_b\) and \(C_u\) are protein-bound and unbound drug concentrations, respectively, at equilibrium; and \(C_{prot}\) is the concentration of binding protein. Since plasma protein binding of cefazolin has been shown to be attributed exclusively to albumin,\textsuperscript{19} \(C_{prot}\) may be replaced by plasma albumin concentration (\(C_{alb}\)). Rearranging Equation 1 yields the following equation:

\[
C_{tot} = \left( \frac{n \cdot C_{alb} \cdot C_u}{K_D + C_u} \right) + C_u \quad (2)
\]

where \(C_{tot}\) is total drug concentrations. Note that the dissociation constant (\(K_D\)) equals \(1/K_a\) by definition. We assume that CPB alters plasma albumin concentration but not the binding affinity of albumin to cefazolin. We also assume that the equilibrium of drug-protein binding is attained rapidly. Solving Equation 2 for \(C_u\), the following equation is obtained\textsuperscript{19}:

\[
C_u = \frac{1}{2} \times \left( \frac{C_{tot} - n \cdot C_{alb} \cdot K_D}{1 + K_D - K_D} + \sqrt{(C_{tot} - n \cdot C_{alb} - K_D)^2 + 4 \cdot K_D \cdot C_{tot}} \right) \quad (3)
\]

By substituting \(C_{tot}\), \(C_{alb}\), and \(K_D\) into Equation 3, we estimated \(C_u\) for each plasma sample. Here, \(C_{tot}\) and \(C_{alb}\) were measured in the plasma samples collected from patients during surgery, and \(K_a\) was obtained from the literature.\textsuperscript{19} Then, we compared plasma unbound cefazolin concentrations (\(C_u\)) that were estimated by Equation 3 and those actually measured.

### 2.7 Statistical analyses

Demographic variables of the participants are presented as mean ± SD with range. Data of unbound fraction of cefazolin and plasma albumin concentration are presented using box and whisker plots. Nonparametric multiple comparisons of plasma unbound fraction of cefazolin and plasma albumin concentration before skin incision, during CPB, and at the end of CPB were performed using the Steel-Dwass’ test for pair-wise comparisons. Correlation between observed unbound cefazolin concentration and estimated concentration was analyzed by the least-squares linear regression. A P value less than 0.001 was considered statistically significant.

### 3 RESULTS

#### 3.1 Patient characteristics and adverse drug reactions

Twenty-seven patients (18 males and nine females, aged 44-93 years) were enrolled in the study and all subjects completed the study (Table 1). The mean CPB duration was 206 minutes (range: 129 to 305 minutes). None of them had major intraoperative complications or adverse drug reactions attributable to cefazolin and other drugs used during surgery. None of them developed SSI within 30 days after the operation.

#### 3.2 Plasma total and unbound cefazolin concentrations during surgery

The time courses of plasma (total and unbound) cefazolin concentrations and albumin concentration obtained from a representative patient before and during surgery are shown in Figure 2. The patient received four doses of cefazolin, since the operation took more than 8 hours. While all plasma unbound cefazolin concentrations measured throughout the surgery were higher than the target threshold for unbound drug (8 \(\mu\)g mL\(^{-1}\)), trough unbound concentrations measured before skin incision, at the beginning of CPB, and before wound closure were close to the threshold concentration. Plasma total cefazolin concentrations were higher than 40 \(\mu\)g mL\(^{-1}\) throughout the surgical procedures. Plasma total and unbound cefazolin concentration obtained from patients immediately before skin incision, at the initiation of CPB or trough before CPB, during CPB, and at wound closure are shown in Table 2. Total and unbound cefazolin concentrations measured during surgery were almost all higher than the respective target concentrations. Especially, 99% (198 of 199 samples) of the plasma concentrations of unbound cefazolin measured during surgery were higher than 8 \(\mu\)g mL\(^{-1}\). Since plasma unbound fraction of the drug far exceeded 20% in samples obtained during and after CPB (Figure 3), a target threshold of total plasma concentration of cefazolin should have been considered lower than 40 \(\mu\)g mL\(^{-1}\). Nevertheless, 99% of total plasma cefazolin concentrations measured during surgery exceeded this value in our study.

Plasma unbound fractions of cefazolin and albumin concentrations obtained before skin incision, during CPB, and at the end of CPB are shown in Figure 3. The median plasma unbound fraction of

### Table 1 Demographic, laboratory and relevant cardiopulmonary bypass (CPB) parameters of patients

| Characteristics                  | Data                        |
|----------------------------------|-----------------------------|
| Gender (male/female)             | 18/9                        |
| Age (years)                      | 70 ± 12 [39-93]             |
| Body weight (kg)                 | 62 ± 12 [42.8-91]           |
| Height (m)                       | 1.60 ± 0.11 [1.44-1.81]     |
| Serum creatinine (mg dL\(^{-1}\))| 0.89 ± 0.28 [0.48-1.49]     |
| Estimated GFR (mL min\(^{-1}\))  | 62.6 ± 19.6 [35.8-113]      |
| AST (IU L\(^{-1}\))              | 23 ± 7 [13-42]              |
| Perioperative patient data       |                             |
| Surgical time (min)              | 428 ± 113 [253-674]         |
| Duration of CPB (min)            | 206 ± 51 [129-305]          |
| Priming volume for CPB (mL)      | 1310 ± 200 [1100-1950]      |
| Fresh frozen plasma (mL)         | 871 ± 979 [0-4080]          |
| Blood transfused (mL)            | 674 ± 725 [0-2520]          |
| Solution transfused (mL)         | 2450 ± 780 [1100-4500]      |
| Blood loss during operation (mL) | 2180 ± 1290 [658-5610]      |

Concomitant medications: Fentanyl, remifentanil, propofol

Data are shown as mean ± SD with range in brackets, or number of patients.
Cefazolin measured before skin incision was 21%, but increased during CPB to 45%, and thereafter showed a tendency of returning to the basal level at wound closure (25%) (Figure 3). Significant (P < 0.001) differences were observed between before skin incision and during CPB, and between during CPB and at wound closure. In addition, the median plasma albumin concentration before skin incision was 36 g L\(^{-1}\), but decreased significantly (P < 0.001) during CPB to 27 g L\(^{-1}\), and increased again to 34 g L\(^{-1}\) at wound closure. Significant (P < 0.001) differences were observed between before skin incision and during CPB, and between during CPB and at wound closure (Figure 3).

### 3.3 Comparison between estimated and measured plasma unbound cefazolin concentrations

A total of 199 pairs of data set were available for this analysis. A significant (P < 0.001) linear correlation with a slope close to unity was observed between the estimated plasma unbound cefazolin concentrations (\(C_{u,\text{obs}}\)) and the actually measured concentrations (\(C_{u,\text{measured}}\)):

\[
C_{u,\text{obs}} = 1.05 \times C_{u,\text{measured}} + 1.49 \quad (r = 0.86).
\]

## DISCUSSION

In the present study, we found that the median plasma unbound fraction of cefazolin showed an abrupt and profound increase during CPB (45%) compared to that at preoperative period (21%) (Figure 2). We speculate that these changes may be attributable to dilutional reduction of plasma albumin levels and saturable plasma protein binding of cefazolin.\(^{20}\) Especially, the CPB circuit was primed with approximately 1.3 L of crystalloid solution, and fresh frozen plasma was subsequently administered to compensate blood loss during operation (Table 1). Since cefazolin binds extensively and exclusively to albumin (80%–86%),\(^{6,7}\) the abrupt reduction in plasma albumin concentration during CPB may cause a corresponding increase in unbound fraction of the drug. In addition, as shown by Decroix et al.,\(^{19}\) the plasma protein binding of cefazolin is saturable at higher plasma concentrations. Marked increase of plasma cefazolin concentration was observed at the commencement of CPB due to the addition of 2 g of cefazolin to the priming solution of the CPB.

### TABLE 2 Plasma total and unbound cefazolin concentrations measured at different points during cardiothoracic surgery with cardiopulmonary bypass (CPB)

| Sampling time                  | Before skin incision (n = 27) | At initiation of CPB or trough before CPB (n = 29) | During CPB (n = 89) | At wound closure (n = 54) |
|--------------------------------|--------------------------------|-----------------------------------------------|---------------------|---------------------------|
| Total concentration (\(\mu\)g L\(^{-1}\)) | 79 [55-134]                    | 71 [29-134]                                   | 159 [89-232]        | 140 [60-230]              |
| % below target threshold (40 \(\mu\)g L\(^{-1}\)) | 0                              | 1\(^{a}\)                                     | 0                   | 0                         |
| Unbound concentration (\(\mu\)g L\(^{-1}\)) | 17 [11-35]                     | 15 [6-45.8]                                   | 70 [21-137]         | 44 [13-127]               |
| % below 8 \(\mu\)g L\(^{-1}\)) | 0                              | 1\(^{b}\)                                     | 0                   | 0                         |
| % below 2 \(\mu\)g L\(^{-1}\)) | 0                              | 0                                             | 0                   | 0                         |

Data are shown as medians and ranges in the brackets.

\(^{a}\)A patient with an irregular surgical course showed total and unbound plasma cefazolin concentrations of 35.4 and 8.3 \(\mu\)g L\(^{-1}\), and \(^{b}\)another patient showed total and unbound plasma cefazolin concentrations of 40.4 and 6.0 \(\mu\)g L\(^{-1}\), respectively. After receiving the first dose of cefazolin (1 g) before skin incision, initiation of CPB was delayed until 366 min from the first dose due to difficulties in operation, and he received the second dose of cefazolin before the initiation of CPB. The total and unbound plasma trough concentrations obtained immediately before the second dose (at 270 min from the first dose) were 40.4 and 6.0 \(\mu\)g L\(^{-1}\), respectively. Total and unbound plasma drug concentrations measured at the initiation of CPB were higher than the respective target concentrations.
circuit. Our speculation may be supported by our finding of a good agreement between the unbound drug concentrations in plasma estimated using the Langmuir model and the concentrations actually measured. We estimated unbound cefazolin concentrations assuming that CPB affects the maximum binding capacity (i.e., plasma albumin concentration) but not the binding affinity of cefazolin binding. Nevertheless, we cannot completely exclude the possibility that heparin-induced elevation of plasma free fatty acids is associated with the increased unbound fraction of cefazolin. Heparin is routinely used for anticoagulation during CPB, and it increases the activity of lipoprotein lipase in tissues and plasma, thereby increasing nonesterified (free) fatty acids concentrations. Fujiwara and Amisaki demonstrated that free fatty acids compete with drug binding at the warfarin-binding site of human albumin. Cefazolin has been shown to bind to this site. While we added tetrahydrolipstatin during blood sampling to prevent in vitro lipolysis after blood sample collection, further studies are necessary to clarify the contribution of free fatty acids to altered plasma protein binding of cefazolin.

There has been an extensive debate over the target plasma unbound concentrations of cefazolin for the prevention of SSI. While 2 μg mL⁻¹ may be enough against the most prevalent pathogen of methicillin-sensitive Staphylococcus aureus (MSSA) and 4 μg mL⁻¹ may be enough against a sensitive Enterobacteriaceae, 8 μg mL⁻¹ may be required for a resistant Enterobacteriaceae. Hollis et al. adopted an inhibitory threshold of 16 μg mL⁻¹ of unbound cefazolin for the validation of a dosing strategy for surgery requiring cardiopulmonary bypass. Recently, Zelenitsky et al reported that cefazolin plasma concentration during wound closure was associated with SSI at 30 days and that total cefazolin closure concentration of 104 μg mL⁻¹ was a significant threshold for an increased risk of infection. In this context, we assessed the performance of our institutional regimen of cefazolin in reference to plasma unbound cefazolin concentrations of 2 and 8 μg mL⁻¹, separately. While concurrent guidelines recommend administration of the first dose of cefazolin (1 or 2 g) within 60 minutes prior to skin incision and the second dose at wound closure, with or without supplemental doses (1 g) every 4 hours during operation, our protocol stipulates the administration of a supplemental dose (2 g) at the initiation of CPB (Figure 1). We demonstrated that our dosing protocol of cefazolin for antimicrobial prophylaxis used in our facility for patients undergoing cardiothoracic surgery with CPB (Figure 1) provides plasma unbound drug concentrations largely exceeding (99% of 199 samples) the target threshold of 8 μg mL⁻¹ throughout the duration of surgery ranging up to 473 minutes (Figure 2 and Table 2). Recently, Calic et al evaluated the appropriateness of the traditional cefazolin regimen in patients undergoing cardiac surgery with CPB (Figure 1) and found that plasma total cefazolin concentrations were lower than 40 μg mL⁻¹ in 40% of intraoperative trough samples and 9.8% of samples obtained at wound closure. They estimated that plasma total cefazolin concentration of 40 μg mL⁻¹ corresponded to an unbound drug concentration of 8 μg mL⁻¹, assuming that plasma protein binding of the drug during surgery with CPB was the same as that of healthy subjects (80%-86%).

Our study suggests that they might have underestimated the
appropriateness of their protocol, since we observed a substantial decrease in plasma protein binding of cefazolin during CPB. Caf-farellie et al\textsuperscript{25} also reported that the traditional dosing protocol of cefazolin was unable to maintain drug concentrations above 8 \( \mu \text{g mL}^{-1} \) in 50\% of the patients when surgical time was longer than 120 minutes. De Cock et al\textsuperscript{26} performed population pharmacokinetic analysis on total and unbound plasma cefazolin concentrations in 54 children undergoing cardiac surgery with CPB. They concluded that an additional bolus dose at the start of CPB may improve the probability of target attainment from 59\% to >94\% in a typical pediatric patient. Collectively, the present study suggests that a supplemental dose of cefazolin at the initiation of CPB may be required for maintaining plasma unbound cefazolin concentration above the threshold level against typical Gram-negative pathogens in adult patients undergoing cardiothoracic surgery with CPB. Obviously, further studies are required to seek for appropriate dosing regimens of cefazolin for pathogen-specific target concentrations.

To establish an effective antimicrobial prophylaxis regimen with cefazolin for patients undergoing cardiothoracic surgery with CPB, we should develop a pharmacokinetic model that describes the disposition of plasma unbound drug during operation. The pharmacokinetics of plasma unbound cefazolin during CPB may be influenced by complex physiological changes associated with the procedure (including low serum albumin levels, transient increase in volume of distribution by connecting the CPB circuit to systemic circulation, changes in circulating volume by infusion and blood loss, and changes in liver and kidney perfusion).\textsuperscript{5,26} The disposition of cefazolin may be particularly susceptible to alteration associated with CPB-induced physiological changes, since the drug has a small volume of distribution (0.19 L kg\(^{-1}\) or 11.4 L per 60 kg) and binds extensively to albumin (80\%-86\%).\textsuperscript{6,7} Miller et al\textsuperscript{13} and Lehot et al\textsuperscript{12} studied the disposition of cefazolin in 8 and 10 adult patients undergoing surgery with CPB, respectively, and reported that the volume of distributions for total plasma cefazolin concentrations was increased during CPB, but they did not measure changes of unbound drug concentrations. Fellinger et al\textsuperscript{27} studied serum unbound cefazolin concentrations in a clinical setting similar to the present study, but they did not perform pharmacokinetic analysis. In this context, a pharmacokinetic analysis of unbound cefazolin concentrations in adult patients undergoing cardiothoracic surgery with CPB is definitely required. Such study is underway in our laboratory and the results will be reported elsewhere.

The present study has some limitations. Due to the small number of participants (\( n = 27 \)) and lack of a comparator group receiving a conventional regimen, we cannot compare the probability of target attainment and the efficacy of antimicrobial prophylaxis between our protocol and the conventional regimen. In addition, we were unable to perform conventional pharmacokinetic analysis of total and unbound plasma cefazolin concentrations, since only a limited number of samples (\( n = 7 \) to 10) were available from each patient. We are examining the possibility of using our datasets to perform a population pharmacokinetic analysis, as mentioned above. For the prevention of SSI, it is important to determine the target site drug concentrations. Douglas et al measured the subcutaneous interstitial fluid (ISF) concentrations of cefazolin in patients undergoing elective/semi-elective abdominal aortic aneurysm open repair surgery and reported that the penetration of unbound drug from plasma to ISF was 85\% (78\% to 106\%).\textsuperscript{28} Thus, the plasma concentration of unbound cefazolin would reflect the drug concentration at the target site.

In conclusion, our results indicate that altered plasma protein binding of the drug during and after CPB should be taken into consideration when modeling the disposition of unbound drug concentrations. Individualization of antimicrobial prophylaxis with cefazolin for adult patients undergoing CPB may be performed using a comprehensive pharmacokinetic modeling taking into account CPB-induced physiological changes.

**ACKNOWLEDGEMENTS**

The study was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP17H00452. The authors appreciate the staff of operation room for their assistance in the study.

**DISCLOSURE**

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

**ORCID**

Masashi Nagata \( \text{http://orcid.org/0000-0003-3169-7210} \)

**REFERENCES**

1. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health-Syst Pharm*. 2013;70:195-283.
2. Morisaki A, Hosono M, Sasaki Y, et al. Evaluation of risk factors for hospital mortality and current treatment for poststernotomy mediastinitis. *Gen Thorac Cardiovasc Surg*. 2011;59:261-267.
3. Kreter B, Woods M. Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trials. *J Thorac Cardiovasc Surg*. 1992;104:590-599.
4. Lador A, Nasir H, Mansur N, et al. Antibiotic prophylaxis in cardiac surgery: systematic review and meta-analysis. *J Antimicrob Chemother*. 2012;67:541-550.
5. Park F, Sime FB, Lipman J, Roberts JA. Dosing antibiotic prophylaxis during cardiopulmonary bypass-a higher level of complexity? A structured review. *Int J Antimicrob Agents*. 2017;49:395-402.
6. Kirby WM, Regamey C. Pharmacokinetics of cefazolin compared with four other cephalosporins. *J Infect Dis*. 1973;128:341-346.
7. Calic D, Ariano RE, Arora RC, et al. Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass. *J Antimicrob Chemother*. 2018;73:768-771.
8. De Smet R, Van Kaer J, Liebich H, et al. Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact. *Clin Chem*. 2001;47:901-909.
9. Gedney JA, Ghosh S. Pharmacokinetics of analgesics, sedatives and anaesthetic agents during cardiopulmonary bypass. Br J Anaesth. 1995;75:344-351.

10. Mets B. The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass. Acta Anaesthesiol Scand. 2000;44:261-273.

11. Edwards F, Engelman R, Houck P, Shahian D, Bridges C. The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, Part I: duration. Ann Thorac Surg. 2006;81:397-404.

12. Lehot JJ, Reverdy ME, Etienne J, et al. Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. J Cardiothorac Anesth. 1990;4:204-209.

13. Miller KW, McCoy HG, Chan KK, et al. Effect of cardiopulmonary bypass on cefazolin disposition. Clin Pharmacol Ther. 1980;27:550-556.

14. Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53 (6):982-992.

15. Krebs M, Stingl H, Nowotny P, et al. Prevention of in vitro lipolysis by tetrahydrolipstatin. Clin Chem. 2000;46:950-954.

16. Hadváry P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J. 1988;256:357-361.

17. Nygard G, Khalil SKW. An isocratic HPLC method for determination of cephalosporins in plasma. J Liq Chromatogr. 1984;7:1461-1475.

18. Turnidge JD, Subcommittee on Antimicrobial Susceptibility Testing of the Clinical and Laboratory Standards Institute. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints. Clin Infect Dis 2011;52(7):917-924.

19. Decroix MO, Zini R, Chaumeil JC, Tillement JP. Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs. Biochem Pharmacol. 1988;37:2807-2814.

20. Vella-Brincat JW, Begg EJ, Kirkpatrick CM, Zhang M, Chambers ST, Gallagher K. Protein binding of cefazolin is saturable in vivo both between and within patients. Br J Clin Pharmacol. 2007;63:752-757.

21. Fujiwara S, Amisaki T. Steric and allosteric effects of fatty acids on the binding of warfarin to human serum albumin revealed by molecular dynamics and free energy calculations. Chem Pharm Bull. 2011;59:860-867.

22. Fehske KJ, Müller WE, Wollert U. The location of drug binding sites in human serum albumin. Biochem Pharmacol. 1981;30:687-692.

23. Hollis AL, Heil EL, Nicolau DP, Odonkor P, Dowling TC, Thom KA. Validation of a dosing strategy for cefazolin for surgery requiring cardiopulmonary bypass. Surg Infect (Larchmt). 2015;16:829-832.

24. Zelenitsky SA, Calic D, Arora RC, et al. Antimicrobial prophylaxis for patients undergoing cardiac surgery: intraoperative cefazolin concentrations and sternal wound infections. Antimicrob Agents Chemother. 2018; https://doi.org/10.1128/AAC.01360-18

25. Caffarel AD, Holden JP, Baron EJ, et al. Plasma cefazolin levels during cardiovascular surgery: effects of cardiopulmonary bypass and profound hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 2006;131:1338-1343.

26. De Cock PA, Mulla H, Desmet S, et al. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery. J Antimicrob Chemother. 2017;72:791-800.

27. Fellinger EK, Leavitt BJ, Hebert JC. Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery. Ann Thorac Surg. 2002;74:1187-1190.

28. Douglas A, Udy AA, Wallis SC, et al. Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. Antimicrob Agents Chemother. 2011;55:5238-5242.

How to cite this article: Asada M, Nagata M, Mizuno T, et al. Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery. Pharmacol Res Perspect. 2018;e00440. https://doi.org/10.1002/prp2.440